Acute Angle-Closure Glaucoma After Hours
A 58-year-old woman of Chinese descent presents at 8 a.m. with a 10-hour history of severe right-eye pain, blurred vision, and colored halos around lights. She also reports nausea and vomited once. She has no prior ocular history and takes hydrochlorothiazide for hypertension; she denies any eye drops or trauma. Visual acuity is 20/200 OD and 20/20 OS. Goldmann applanation pressure is 54 mmHg OD and 16 mmHg OS. The right eye shows intense circumlimbal injection, a steamy cornea, a fixed 6-mm pupil, and a markedly shallow peripheral anterior chamber. The left eye has a shallow peripheral anterior chamber with a plateau-iris configuration and a patent-appearing angle on gonioscopy. The right fundus cannot be viewed. She is systemically stable except for a blood pressure of 168/94 mmHg and a heart rate of 96 beats/min. She asks whether she can be treated as an outpatient and return tomorrow.
1. What is your diagnosis, and what immediate pharmacologic management would you initiate? Explain the rationale for each agent and why outpatient discharge is inappropriate.
Read the worked answer
Diagnosis: acute angle-closure glaucoma. The combination of severe pain, nausea, halos, a mid-dilated fixed pupil, a shallow anterior chamber, and an IOP of 54 mmHg is classic; the fellow eye is at high risk because of its plateau-iris configuration.
Immediate goals are to lower IOP, clear the cornea, relieve pain, and protect the optic nerve.
- Topical beta-blocker (timolol 0.5% one drop): reduces aqueous production. Avoid in reactive airway disease or marked bradycardia.
- Topical alpha-2 agonist (brimonidine 0.15–0.2%): reduces production and increases uveoscleral outflow.
- Topical carbonic anhydrase inhibitor (dorzolamide 2%): additive suppression of aqueous production.
- Systemic carbonic anhydrase inhibitor (acetazolamide 500 mg IV or oral): rapid IOP reduction; check sulfa allergy, renal function, and sickle cell status.
- Hyperosmotic agent (20% mannitol 1–2 g/kg IV over 30–45 minutes, or oral glycerin): draws fluid from the vitreous; caution in heart failure and renal disease.
- Pilocarpine 2% after IOP begins to fall: the ischemic iris sphincter may not respond at very high pressure, but once perfusion improves, miosis pulls the iris away from the trabecular meshwork.
She should not be discharged until IOP is controlled and pain is manageable. Add an antiemetic and analgesia, avoid anticholinergic and sympathomimetic agents that can worsen angle closure, and arrange urgent definitive treatment once the cornea clears. If IOP remains uncontrolled on maximal therapy, refer for surgical intervention.
2. Once the cornea clears, what definitive treatment do you recommend for this eye and the fellow eye, and what follow-up is required?
Read the worked answer
Definitive treatment: laser peripheral iridotomy (LPI), ideally within 24–48 hours once the cornea is clear enough to visualize the iris. LPI creates an alternate pathway for aqueous flow from the posterior to the anterior chamber, relieving pupillary block, which is the usual mechanism here. If the angle remains appositional despite a patent LPI, consider argon laser peripheral iridoplasty or lens extraction, particularly if the lens is large and anteriorly positioned.
Fellow eye: treat prophylactically with LPI. The left eye has a shallow anterior chamber and plateau configuration and is at substantial risk for a second acute attack, which can cause permanent visual loss. Bilateral LPI is standard. If the patient declines or LPI is not feasible, counsel about warning symptoms and arrange close follow-up.
Follow-up: reassess IOP, gonioscopy, and optic nerve status after LPI. Some patients develop chronic angle closure or elevated IOP and require ongoing glaucoma therapy. Schedule visits at 1 week and then 1–3 months, with baseline visual fields and optic nerve imaging. If the attack caused optic neuropathy, set a target IOP based on risk factors and treat as chronic glaucoma. Also monitor for cataract and corneal endothelial damage from the acute pressure spike.
3. What complications would you warn the patient about, and how would you modify management if the IOP remains above 30 mmHg despite maximal topical and systemic therapy?
Read the worked answer
Complications to discuss: permanent optic nerve damage and visual field loss if IOP remains elevated; corneal endothelial damage and persistent corneal edema; cataract formation; recurrence in either eye; and, rarely, malignant glaucoma or retinal vascular occlusion. The risk of optic nerve injury rises with duration of high pressure, so the urgency of definitive treatment should be explicit.
If IOP remains above 30 mmHg despite maximal medical therapy: do not continue outpatient observation. Reassess whether the angle is truly appositional and whether the diagnosis is correct. Escalate to urgent surgical management, such as trabeculectomy, glaucoma drainage device, or lens extraction, depending on the anterior segment anatomy and lens status. In some cases, anterior chamber paracentesis or a temporary surgical iridectomy may be needed to break the attack. Consult a glaucoma specialist immediately. Continue aqueous suppression and hyperosmotic therapy while arranging surgery, and monitor for corneal decompensation. After surgery, follow IOP, inflammation, and optic nerve function closely. The key judgment is that uncontrolled pressure after appropriate medical therapy is a surgical emergency, not a reason for a later appointment.